{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["Sheet1"],"not_rendered":{"external_links":1,"defined_names":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet1","index":0,"n_rows":33,"n_cols":29,"rows_kept":33,"merged":[[0,0,0,28],[1,7,1,8],[1,15,1,16],[1,17,1,18],[1,19,1,20],[1,21,1,22],[1,23,1,24],[1,25,1,26],[1,28,2,28],[32,0,32,28]],"flags":["formulas_cached_only"]}
["Table 2. Characteristics of Included Trials"]
[{"$nulls":7},"Sample Size",null,"Sex Ratio",{"$nulls":5},"Mortality",null,"PaO2/FiO2 Ratio ( Day 7)",null,"Ventilator-free days",null,"Ventilator days",null,"ICU stay",null,"ICU-free day",null,null,"No. of Participants Dropout or Withdrawal"]
[null,"Study","Control","Interventions","Dose*Treatment duration","Route","Time of enrollment","Treatment","Control","Male: Femal","Age, year","Primary End Point","Mortality Outcome","Mortality Rate of Control Group","PaO2/FiO2 ratio of Control Group","Treatment","Control","Treatment","Control","Treatment","Control","Treatment","Control","Treatment","Control","Treatment","Control","Blind"]
["Albumin"]
[null,"Martin et al, 2003","Equivalent volume of 0.9% sodium chloride solution","25% human serum albumin","75g/d*5d","Intravenous","NA",19,18,"24:13",42.4,"Change in weight over a 5-day period","30-day mortality","3/18(16.67%)",197,"3/19","3/18","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Double-blind","0"]
[null,"Martin et al, 2005","Equivalent volume of 0.9% sodium chloride solution","25% human serum albumin","75mg/d*3d","Intravenous","NA",20,20,"19:21",47.65,"Change in oxygenation over a 24-hr period","30-day mortality","9/20(45.00%)",182,"7/20","9/20","NA","NA",5.5,"1(95% CI -2.5~11.5)","NA","NA","NA","NA","NA","NA","Double-blind","0"]
[]
["Antioxidants"]
[null,"Teodoro et al, 2011","Isocaloric control diet","EPA+DHA+GLA+antioxidants","Caloric were set at 25 kcal/kg/day and protein intake at 1.5 g/kg/day","Enteral feeding","NA",61,71,"102:30",63,"New organ dysfunction","28-day mortality","11/71 (15.49%)",122,"11/61","11/71",217,190,"NA","NA",10,9,16,18,"NA","NA","Single-blind",28]
[null,"Gadek et al, 1999","Isonitrogenous and isocaloric control diet","EPA+GLA+antioxidants","NA","Enteral feeding","Within 24 hrs of meeting entrance criteria",51,47,"52:46",51,"Time receiving ventilatory support,time in the ICU, and time on supplemental oxygen","Hospital mortality","9/47(19.15%)","NA","6/51","9/47","NA","NA","NA","NA","9.6±0.9","13.2±1.4","11.0±0.9","14.8±1.3","NA","NA","Double-blind",33]
[null,"Pierre et al, 2006","Isonitrogenous and isocaloric control diet","EPA+GLA+antioxidants","NA","Enteral feeding","Within 24 hrs of ICU admission","50(46)","50(49)","57:38",59.73,"Change in oxygenation and breathing patterns","Hospital mortality (14-day)","17/49(34.69%)","230.5±58.7","20/46","17/49","296.5±165.3","236.3±79.8","NA","NA","NA","NA","NA","NA","NA","NA","Unblinded",5]
[null,"Elamin et al, 2012","Isonitrogenous and isocaloric control diet","EPA+DHA+GLA+antioxidants","NA","Enteral feeding","NA","11(9)","11(8)","8:9",52.4,"Oxygenation and modified lung injury scores","28-day mortality","1/8(12.5%)","NA","0/9","1/8",178,201,"NA","NA",6.7,8.2,12.8,17.5,"NA","NA","Double-blind",3]
[null,"Kunihiro et al, 2015","Isocaloric control diet","EPA+GLA+antioxidants","NA","Enteral feeding","NA","23(20)","23(20)","34:12",72.5,"Duration of mechanical ventilation","60-day mortality","3/23(13.04%)","NA","3/23","3/23",297,244.5,14,11,"13.61±1.00","17.77±1.81","17.63±1.70","25.87±2.6",13,4,"Single-blind",6]
[null,"Rice et al, 2012","Isocaloric and isovolemic control diet","EPA+DHA+GLA+antioxidants","NA","Bolus delivery","NA",143,129,"133:139",54.1,"Ventilator-free days","60-day or hospital mortality","21/129 (16.28%)","172.5±84.6","38/143","21/129","NA","NA","14.0±11.1","17.2±10.2","NA","NA","NA","NA","14.0±10.5","16.7±9.5","Double-blind",0]
["NAC"]
[null,"Bernard et al, 1997","Dextrose 5% in water","NAC","70mg/kg/8h*10d","Intravenous","Within 48 hrs",14,15,"NA",47.53,"NA","30-day mortality","6/15(40.00%)","159±19","5/14","6/15","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Double-blind",2]
[null,"Guido et al, 1997","NA","NAC","190mg/kg/d*3d","Intravenous","NA",22,20,"33:9",52.24,"NA","ICU mortality","5/20(25%)","133±37","7/22","5/20","NA","NA","NA","NA","8.1±6.5","9.3±6.6","13.8±7.2","18.5±8.6","NA","NA","Double-blind",0]
[null,"Ortolani et al, 2000","Dextrose 5% in water","NAC or NAC+rutin","50mg/kg","Intravenous","NA",24,12,"19:17",56,"NA","30-day mortality","7/12(58.33%)","160±21","9/24","7/12","187.5(day 6)","170±18(day 6)","NA","NA","NA","NA","NA","NA","NA","NA","Unblinded",0]
[null,"Jepsen et al, 1992","NA","NAC","150mg/kg/d*1d+20mg/kg/h*6d","Intravenous","NA",32,34,"39:27",50.97,"NA","60-day mortality","17/34(50.00%)",151,"17/32","17/34",170,199,"NA","NA","NA","NA","NA","NA","NA","NA","NA",0]
[null,"Moradi et al, 2009","Dextrose 5% in water","NAC","150mg/kg/d*1d+50mg/kg/d*3d","Intravenous","The clinical diagnoses of ALI/ARDS were established","15(14)","15(13)","17:10",48.79,"NA","Hospital mortality","10/13(76.92%)","139.1±15.3","5/14","10/13","NA","NA","NA","NA","24.8±8.5","32.9±9.8","32.9±7.6","42.1±10.3","NA","NA","Single-blind",3]
[null,"Peter et al, 1993","NA","NAC","40mg/kg/d*3d","Intravenous","NA",32,29,"47:14",47.31,"NA","Hospital mortality","10/29(34.48%)","248±99","7/32","10/29","NA","NA","NA","NA","NA","NA","11.3±10.5","12.2±9.6","NA","NA","Double-blind",0]
["Selenium"]
[null,"Mahmoodpoor et al, 2019 ","Equal volume of normal saline","Sodium selenite","4mg(first day)+2mg(2-4 day)+1mg(5-10day)","Intravenous","NA","20 (72)","20 (67)","24:16",57.5,"Antioxidant capacity of the lungs and blood","Hospital mortality","16/67(23.88%)","55.9±1.2","11/72","16/67","72.4±2.7","66.6±2.5","NA","NA","13.2±6.7","14.9±6.9","NA","NA","NA","NA","Double-blind",2]
["Vitamin"]
[null,"Fowler et al, 2019 ","Dextrose 5% in water","Vitamin C","50 mg/kg/6h*96h","Intravenous","Within 6 hours of randomization ","86(84)","84(83)","90:77",55.49,"Modified Sequential Organ\nFailure Assessment scores and plasma biomarker levels","28-day mortality","38/82(46.34%)",214.5,"25/84","38/82","NA","NA",13.1,"10.6(95% CI -0.90~5.85)","NA","NA","NA","NA",10.7,"7.7(95%CI 0.3~5.9","Double-blind",3]
["Oxothiazolidine-4-carboxylic acid"]
[null,"Bernard et al, 1997","Dextrose 5% in water","Oxothiazolidine-4-carboxylic acid","63mg/kg/8h*10d","Intravenous","Within 48 hrs",17,15,"NA",47.53,"NA","30-day mortality","6/15(40.00%)","159±19","6/17","6/15","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","Double-blind",2]
[null,"Peter et al, 2008","Dextrose 5% in water","Oxothiazolidine-4-carboxylic acid","70mg/kg/8h*14d","Intravenous","Within 24 hrs of meeting the chest radiograph criterion; within 48 hrs of first meeting the PaO2/FIO2 criterion; ","101(100)",114,"125:89",50,"Ventilator-free days","30-day mortality","18/114(15.79%)","117.5±44.9","29/100","18/114","NA","NA","8.3±9.8","13.5±10.6","NA","NA","NA","NA","NA","NA","Double-blind",1]
["Lisofylline"]
[null,"ARDS Network, 2002","NA","Lisofylline","3.0 mg/kg/6h*20d","Intravenous","Enrolled within 36 hrs of diagnosed ARDS.",116,119,"145:90",51,"28-day mortality","28-day mortality","29/119(24.37%)","153±7","37/116","29/119","NA","NA","NA","NA",9,11,"NA","NA","NA","NA","Double-blind",0]
[]
[]
["Abbreviations: NA=Not Applicable, ICU=Intensive Care Unit"]